Immuneering Corporation - Class A (IMRX)
IMRX moved a median of -0.36% 30 minutes after news, and -1.61% by the close. How IMRX actually reacts to news — the realized, point-in-time move the market made, measured across 253 labeled events over the last three years with zero look-ahead.
IMRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 39% | 253 |
| 30-min | -0.36% | 47% | 253 |
| 60-min | -0.51% | 44% | 253 |
| to close | -1.61% | 42% | 250 |
| Middle 50% of IMRX reactions | -2.29% to +2.15% |
|---|---|
| Median reaction (30-min) | -0.36% |
| Measured reactions | 253 |
Half of all Immuneering Corporation - Class A news events land between -2.29% and +2.15% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How IMRX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 14 | -13.70% | 21% | -21.95% |
| Coverage initiations | 12 | +3.88% | 83% | +7.17% |
| Rating reiterations | 68 | -0.00% | 50% | -1.04% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how IMRX ranks against every other measured name →
That’s how IMRX usually reacts — get an email when it moves on news →Email me when IMRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to IMRX's baseline. Nothing else.
Recent IMRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) | Press release | GlobeNewswire | -0.49% | -0.73% | |
| Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer | Press release | GlobeNewswire | -0.47% | -2.12% | |
| Immuneering to Present at the ESMO Congress 2026 | Press release | GlobeNewswire | +0.12% | -0.46% | |
| Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival | Press release | GlobeNewswire | +0.41% | +0.88% | |
| Immuneering to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.10% | -2.43% | |
| Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients | Press release | GlobeNewswire | -0.19% | +0.39% | |
| Form 10-Q Immuneering Corp For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.90% | -1.57% | |
| Form 8-K Immuneering Corp For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -0.90% | -1.57% | |
| Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates | Press release | GlobeNewswire | -0.90% | -1.57% | |
| Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition | Press release | GlobeNewswire | +1.47% | +1.36% | |
| Immuneering Corporation Announces Grants of Inducement Awards | Press release | GlobeNewswire | +1.26% | -10.06% | |
| Form 8-K Immuneering Corp For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +0.45% | -2.15% | |
| Immuneering Appoints Andrew Gengos as Chief Financial Officer | Press release | GlobeNewswire | -0.23% | -1.87% | |
| Form 8-K Immuneering Corp For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | -0.97% | +1.95% | |
| Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer | Press release | GlobeNewswire | -0.76% | +4.57% | |
| Form 8-K Immuneering Corp For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | -5.18% | -5.73% | |
| Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO | Press release | GlobeNewswire | -12.28% | -20.58% | |
| Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy | Press release | GlobeNewswire | +2.75% | -10.02% | |
| Form 10-Q Immuneering Corp For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.15% | +1.18% | |
| Form 8-K Immuneering Corp For: May 15 | SEC filing · Form 8-K | SEC EDGAR | +1.15% | +1.18% | |
| Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates | Press release | GlobeNewswire | +1.15% | +1.18% | |
| Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting | Press release | GlobeNewswire | +0.63% | +5.37% | |
| Form DEF 14A Immuneering Corp For: Apr 20 | SEC filing · Form DEF | SEC EDGAR | -0.36% | +0.18% | |
| Form DEFA14A Immuneering Corp | SEC filing · Form DEFA14A | SEC EDGAR | -0.36% | +0.18% | |
| Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond | Press release | GlobeNewswire | +0.72% | -0.72% | |
| Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference | Press release | GlobeNewswire | -1.49% | -2.42% | |
| Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival | Press release | GlobeNewswire | +0.44% | -0.83% | |
| Form 10-K Immuneering Corp For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.96% | +9.90% | |
| Form 8-K Immuneering Corp For: Mar 06 | SEC filing · Form 8-K | SEC EDGAR | +1.96% | +9.90% | |
| Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates | Press release | GlobeNewswire | +1.96% | +9.90% | |
| Immuneering to Present at the Leerink Global Healthcare Conference | Press release | GlobeNewswire | +1.33% | +1.43% | |
| Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | GlobeNewswire | -1.40% | +5.00% | |
| Form 8-K Immuneering Corp For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | -4.82% | -18.59% | |
| Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP | Press release | GlobeNewswire | -4.82% | -18.59% | |
| Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 | Press release | GlobeNewswire | -0.34% | +7.21% | |
| Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA | Press release | GlobeNewswire | +2.62% | +2.53% | |
| Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) | Press release | GlobeNewswire | +1.04% | +0.00% | |
| Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance | Press release | PR Newswire | -0.79% | -4.55% | |
| Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference | Press release | GlobeNewswire | -1.53% | -1.06% | |
| Form 10-Q Immuneering Corp For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.61% | — | |
| Form 8-K Immuneering Corp For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +1.61% | — | |
| Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates | Press release | GlobeNewswire | +1.61% | — | |
| Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025 | Press release | GlobeNewswire | -0.16% | +0.47% | |
| Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 | Press release | GlobeNewswire | -1.12% | -15.94% | |
| Form 8-K Immuneering Corp For: Sep 24 | SEC filing · Form 8-K | SEC EDGAR | -2.38% | +0.37% | |
| Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi | Press release | GlobeNewswire | -11.26% | -16.58% | |
| Form 8-K Immuneering Corp For: Sep 24 | SEC filing · Form 8-K | SEC EDGAR | -11.26% | -16.58% | |
| Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP | Press release | GlobeNewswire | -11.26% | -16.58% | |
| Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi | Press release | GlobeNewswire | -11.26% | -16.58% | |
| Immuneering Appoints Dr. Thomas Schall as Chairman of the Board | Press release | GlobeNewswire | +3.90% | +4.66% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the IMRX section they belong to.
Where else IMRX is measured.
IMRX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Immuneering Corporation - Class A's median reaction calculated?
Every labeled IMRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 253 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of IMRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does IMRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.